menu
    • menu
    [{"orgOrder":0,"company":"BiomX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered Phage Therapy","moa":"","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"BiomX \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Egineered Treg Cell Therapy","moa":"Treg Cell","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/ Bristol Myers Squibb"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nexilico

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexilico

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Microbial-based Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Sponsor : Siolta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nexilico and Siolta Partner On Microbiome Drug For Necrotizing Enterocolitis

                            Details : The collaboration combines Nexilico's AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for the treatment approaches in infant health.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Microbial-based Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Sponsor : Siolta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vivtex

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vivtex

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrocycle-based Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Sponsor : Orbis Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbis and Vivtex Partner To Develop Oral nCycles Drugs

                            Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.

                            Brand Name : nCycles

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Macrocycle-based Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Sponsor : Orbis Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GentiBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            GentiBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Egineered Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammato...

                            Details : GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 10, 2022

                            Lead Product(s) : Egineered Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BiomX

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BiomX

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Phage Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

                            Details : Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 28, 2022

                            Lead Product(s) : Engineered Phage Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth